Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults

NCT06526208 | Recruiting Phase 2 DMC FDA Drug

• 2 other identifiers: 168788RFGA2022-009-001
• Study Type: interventional
• Target: 108
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to learn if drug ABC works to treat severe asthma in adults. It will also learn about the safety of drug ABC. The main questions it aims to answer are: Will a marijuana-based drug help anxiety in autistic adults? Anxiety can make socializing and working more difficult for people. Researchers will compare a marijuana based drug (that is mostly CBD with a small amount of THC) to a placebo (a look-alike substance that contains no drug) to see if the drug makes symptoms of anxiety better. Participants will take the drug (or a placebo) every day for 8 weeks and keep a diary to record the time they took the drug, and their feelings each day. The drug is taken orally in drops once or twice a day. The study staff will speak to the participants weekly either over the phone or in the clinic. Clinic visits once every 2 weeks for checkups and tests. The researchers will make sure participants are healthy and see if there are any changes in anxiety.

Conditions

Anxiety; Autism Spectrum Disorder

Keywords

Autism; Anxiety; marijuana; cannabis; CBD; THC

Outcome Measures

Primary Outcomes (1)

• Change in baseline on reported anxiety related symptoms

  The Clinical Global Impression Scale for Severity will be used to measure the change in anxiety related symptoms. We hypothesize a two point reduction in severity and

  8 weeks

Secondary Outcomes (3)

• Change in socialization

  8 weeks

• Change in repetitive behaviors from baseline to the end of study

  8 weeks.

• We will measure the change in a variety of aberrant behaviors from baseline to end of study

  8 weeks

Study Arms (2)

MB-IMP Group

ACTIVE COMPARATOR

Participants in this group will receive the MB-IMP, an oil-based solution that will contain CBD and THC (23:1 ratio, respectively) and be taken orally. Participants or study partners will dispense the daily dose with an eye dropper according to instructions from the Principal Investigator or delegated study coordinator. Dosing will start at 0.25 ml per day (50 mg of CBD and 2.18 mg of THC). The dose will gradually increase to 1.0 ml per day (200 mg of CBD, and 8.7 mg of TCH) by week 4. Weeks 5 through 8 will be at the maximum dose, 2 ml per day (400 mg of CBD and 17.4 mg of THC). With the exception of week 1 at the lowest dose (0.25 ml), participants will dose in the morning and evening to reach the maximum dose for that time period.

Drug: MB-IMP

Placebo Group

PLACEBO COMPARATOR

Participants will follow the same dosing instructions for the MB-IMP group, but will take only MCT oil.

Other: Placebo

Interventions

MB-IMP DRUG

MB-IMP is a marijuana-based investigational medical product. It contains a 23:1 ratio of CBD to THC, is an oil-based tincture that is taken orally.

Also known as: MCT oil

MB-IMP Group

Placebo OTHER

Does not contain CBD or THC

Also known as: Medium Chain Triglyceride (MCT) oil

Placebo Group

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Male or female age 18 to 45 years old with an autism diagnosis.
• Participant is ≥ 100 lbs.
• Participant or a legally authorized representative provides informed consent/assent for participation in the trial.
• Participant/caregiver is willing and able to comply with all study procedures.
• Participant meets ADOS-2 criteria for Autism or Autism Spectrum
• Participant meets DSM-5 criteria for ASD.
• Participant has a minimum CGI-S (Anxiety) score ≥ 5 based on anxiety related social functional impairment.
• Participant has a FSIQ ≥ 65 at screening measured with the WASI- II, or within 1 year of screening with a comparable assessment.
• Participant must have a negative pregnancy test (urine and serum) at Screening, and a negative urine test at Baseline, Active Phase Visits, and EoS visits, see Table 1. Schedule of Activities.
• Sexually active participants agree to use two methods of effective birth control, as described in Appendix B: Contraceptive and Barrier Guidance during the study intervention period and for at least 14 days after the Study Termination visit.
• Participant must be stable on any pre-study medications and/or psychotherapy for 6-weeks prior to study enrollment, agree to inform prescribing clinician(s) about participation in the study, and agree to maintain medication or psychotherapy treatment regimen during the study.
• Participant must be able to ingest MB-IMP (or placebo) and be willing to commit to medication dosing and completing the dosing diary.
• Participant/caregiver agrees to keep all study medication provided by site staff securely stored at home and not to share/distribute study medication to any other individual.
• Participant agrees not to participate in any other interventional clinical trials during the study period.
• Participant agrees to inform the investigators within 48- hours of any side-effects, medical conditions, and procedures.

You may not qualify if:

• Participant weighs \< 100 lbs.
• Participant is sexually active and does not practice two effective forms of birth control.
• Participant is pregnant, lactating, or planning pregnancy during the study period or within 12 weeks thereafter.
• Participant has a current or historical psychotic features/disorder assessed via the Mini-International Neuropsychiatric Interview (MINI).
• Participant has a current or historical DSM-5 diagnosis of dissociative identity disorder, positive family history (first-degree relative) of psychotic disorder or bipolar disorder type 1.
• At high risk of suicide or suicide attempts.
• Individuals presenting current serious suicide risk, as determined through psychiatric interview, responses to the Columbia Suicide Severity Rating Scale (C-SSRS), and/or clinical judgment of the investigator.
• History of suicide attempts within 12 months prior to study enrollment.
• Participant has a current substance use disorder within the 12 months prior to enrollment as determined by the MINI Kid56.
• Participant's urine drug screen is positive for opiates, methamphetamine, cocaine, THC, and amphetamines (unless prescribed). Participants with positive THC urine analysis tests are excluded from the study but will be allowed to rescreen (maximum twice) after a 1-month cessation of cannabis use.
• Participant has a history of arrhythmia, other than occasional premature atrial contractions (PACs) and premature ventricular contractions (PVCs) without ischemic heart disease, within 12 months of screening.
• Participant with a history of atrial fibrillation, atrial tachycardia, atrial flutter or paroxysmal supraventricular tachycardia, or any other arrhythmia associated with a bypass tract, may be enrolled only if they have been successfully treated with ablation and have not had a recurrent arrhythmia for at least one year off all antiarrhythmic drugs or are under adequate and stable pharmacologic treatment for atrial fibrillation for at least a year, as confirmed by a cardiologist.
• Participant has a current diagnosis or evidence of significant or uncontrolled hematological, endocrine, cerebrovascular, cardiovascular, coronary, pulmonary, gastrointestinal, renal, immunocompromising, or neurological disease according to PI's discretion.
• Evidence of existing hepatocellular injury defined as alanine transaminase (ALT) and aspertate aminotranferase (AST) elevations of greater than 3 times upper limit normal (ULN) and bilirubin elevation of greater than 2 times ULN.
• The PI or medical monitor deems the participant inappropriate for the study for any reason.

Sponsors & Collaborators

• Southwest Autism Research & Resource Center: lead

Study Sites (1)

Southwest Autism Research and Resource Center

Phoenix, Arizona, 85006, United States

RECRUITING

MeSH Terms

Conditions

Autism Spectrum Disorder; Anxiety Disorders; Autistic Disorder; Marijuana Abuse

Interventions

Oils

Condition Hierarchy (Ancestors)

Child Development Disorders, Pervasive; Neurodevelopmental Disorders; Mental Disorders; Substance-Related Disorders; Chemically-Induced Disorders

Intervention Hierarchy (Ancestors)

Lipids

Study Officials

• Christopher J Smith, Ph.D.

  SARRC

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Christopher J Smith, Ph.D.

CONTACT

602-218-8192; csmith@autismcenter.org

Brian Shaw

CONTACT

602-340-8717; bshaw@autismcenter.org

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 23, 2024
• First Posted: July 29, 2024
• Study Start: May 28, 2025
• Primary Completion (Estimated): September 30, 2026
• Study Completion (Estimated): September 30, 2027
• Last Updated: March 30, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)